China's Bio-Thera Solutions licenses its arthritis drug to Germany's STADA

HONG KONG (Reuters) -China's Bio-Thera Solutions said on Thursday it has granted Germany's STADA Arzneimittel commercialisation rights for its arthritis drug BAT1806 in the EU, UK, Switzerland, certain Middle East and North Africa regions, and certain members of the Commonwealth of Independent States.

Upfront payment and milestone payments will total up to 136 million euros ($158.34 million), including an 8.5 million euro down payment, milestone payments up to 127.5 million euros, and a double-digit percentage of net sales as revenue sharing, the Shanghai-listed firm said in a stock exchange filing.  

($1 = 0.8589 euros)

(Reporting by Hong Kong newsroom; Editing by Christopher Cushing and Muralikumar Anantharaman)